| Literature DB >> 23685669 |
Yoshiharu Ryu1, Hitoshi Shibuya, Keiji Hayashi.
Abstract
Brachytherapy using (198)Au grains is minimally invasive and the only curative treatment for early tongue cancer in patients of advanced age or poor performance status available in our institution. From March 1993 to February 2008, (198)Au grains were used to treat a group of 96 Stage I-II tongue cancer patients who could not undergo surgery or brachytherapy using (192)Ir pins because of an advanced age (≥75 years) or poor performance status (≥2). The patients were followed for 3.9 ± 3.3 years, and the cause-specific survival and local control rates were determined. Survival analyses were performed using the Kaplan-Meier method, and univariate and multivariate analyses were performed using the Cox proportional hazard model. The results were compared with those for a group of 193 early tongue-cancer patients who underwent treatment using iridium pins. The 5-year cause-specific survival and local control rates of the (198)Au grains group were 71% and 68%, respectively, both of which were 16% lower than the corresponding rates for the (192)Ir pins group. Our study demonstrated that as the last curative treatment available, (198)Au grain implantation could be used to achieve moderate treatment results for early tongue cancer in patients of advanced age or poor performance status.Entities:
Keywords: 198Au grain implantation; advanced age; brachytherapy; early tongue cancer; performance status
Mesh:
Substances:
Year: 2013 PMID: 23685669 PMCID: PMC3823781 DOI: 10.1093/jrr/rrt060
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Patient characteristics
| Au-group ( | Ir-group ( | ||
|---|---|---|---|
| Age (yrs) | 71 ± 13 | 60 ± 14 | <0.0001*** |
| Sex (male/female) | 58/38 | 134/59 | 0.15 |
| Male (%) | 60 | 69 | |
| Female (%) | 40 | 31 | |
| T-factor (T1/T2) | 43/53 | 66/127 | 0.09 |
| T1 | 45 | 34 | |
| T2 | 55 | 66 | |
| Complications (%) | 19 | 11 | 0.10 |
| PS (Grade ≤ 1/Grade | (45/51) | (193/0) | <0.0001*** |
| Grade | 47 | 100 | |
| Grade | 53 | 0 | |
| Tumor type | |||
| Superficial (%) | 47 | 49 | 0.71 |
| Exophytic (%) | 42 | 40 | 0.80 |
| Infiltrative (%) | 11 | 11 | 1.0 |
***P < 0.001. Age is presented as the mean ± SD. PS = performance status
Definitions of soft tissue and mandibular complications
| Grade | Soft tissue complication | Mandibular complication |
|---|---|---|
| No ulcer | No change | |
| Transient ulcer disappeared within 6 months | Transient bone exposure disappeared spontaneously | |
| Incurable ulcer lasted over 6 months | Bone necrosis healed by conservative treatment | |
| Severe ulcer necessitating operation | Severe bone necrosis necessitating operation |
Clinical outcomes
| Au-group ( | Ir-group ( | ||
|---|---|---|---|
| Prescribed dose (Gy) | 70 (8) | 70 (0) | |
| Follow-up period (yrs) | 3.9 ± 3.3 | 6.6 ± 4.2 | |
| Deceased patients (tongue cancer) | 2.0 ± 1.4 | 2.0 ± 2.2 | |
| Deceased patients (other cause) | 4.2 ± 5.2 | 5.0 ± 3.3 | |
| Surviving patients | 5.2 ± 3.0 | 7.7 ± 4.0 | |
| Postoperative complications (%) | 8.3 | 19 | 0.02* |
| Grade I (%) | 100 | 69 | |
| Grade II (%) | 0 | 31 | |
| Local recurrence (%) | 28 | 16 | 0.03* |
| Cause-specific death (%) | 26 | 15 | 0.02* |
| Lymph node metastases (%) | 24 | 26 | 0.67 |
| Cause-specific survival rate | 0.003** | ||
| 3 yrs (%) | 73 | 88 | |
| 5 yrs (%) | 71 | 87 | |
| Overall survival rate | 0.001** | ||
| 3 yrs (%) | 57 | 75 | |
| 5 yrs (%) | 51 | 72 | |
| Local control rate | 0.002** | ||
| 3 yrs (%) | 71 | 88 | |
| 5 yrs (%) | 68 | 86 |
The follow-up period is presented as the mean ± SD. The prescribed dosage is presented as the median (interquartile range) because it did not have a normal distribution. *P < 0.05, **P < 0.01.
Fig. 1.Cause-specific survival curves for the Au-group and the Ir-group.
Fig. 2.Local control survival curves for the Au-group and the Ir-group.
Univariate analysis
| Au-group | Local recurrence | Cause-specific death | Lymph node metastasis | |||
|---|---|---|---|---|---|---|
| UHR | UHR | UHR | ||||
| Sex (male vs female) | 0.65 | 0.27 | 0.47 | 0.06 | 0.4 | 0.03* |
| Age | 1.01 | 0.47 | 1.02 | 0.35 | 1.01 | 0.68 |
| Tumor type (superficial) | 0.74 | 0.51 | 0.43 | 0.09 | 0.60 | 0.32 |
| Tumor type (infiltrative) | 2.10 | 0.14 | 2.15 | 0.11 | 3.27 | 0.02* |
| T-factor (T2 vs T1) | 1.98 | 0.11 | 1.15 | 0.72 | 1.34 | 0.49 |
| Prescribed dose | 0.94 | 0.03* | 0.96 | 0.23 | 1.00 | 0.90 |
| Sex (male vs female) | 1.07 | 0.86 | 1.39 | 0.45 | 0.95 | 0.85 |
| Age | 1.00 | 0.78 | 1.01 | 0.49 | 0.99 | 0.25 |
| Tumor type (superficial) | 0.57 | 0.17 | 0.23 | 0.005** | 0.51 | 0.03* |
| Tumor type (infiltrative) | 1.48 | 0.43 | 1.72 | 0.22 | 0.97 | 0.93 |
| T-factor (T2 vs T1) | 1.90 | 0.14 | 1.65 | 0.25 | 1.36 | 0.32 |
| Prescribed dose | 0.99 | 0.90 | 0.97 | 0.65 | 0.98 | 0.65 |
UHR = unadjusted hazard ratio. *P < 0.05, **P < 0.01.
Multivariate analysis
| Au-group | Local recurrence | Cause-specific death | Lymph node metastasis | |||
|---|---|---|---|---|---|---|
| AHR | AHR | AHR | ||||
| Sex (male vs female) | 0.76 | 0.53 | 0.48 | 0.10 | 0.42 | 0.06 |
| Age | 1.01 | 0.68 | 1.01 | 0.55 | 1.00 | 0.92 |
| Tumor type (superficial) | 0.80 | 0.65 | 0.40 | 0.07 | 0.59 | 0.33 |
| Tumor type (infiltrative) | 1.62 | 0.37 | 2.14 | 0.14 | 3.58 | 0.02* |
| T-factor (T2 vs T1) | 1.32 | 0.56 | 0.53 | 0.18 | 0.69 | 0.46 |
| Prescribed dose | 0.95 | 0.10 | 0.97 | 0.29 | 1.01 | 0.82 |
| Sex (male vs female) | 1.08 | 0.85 | 1.35 | 0.50 | 0.92 | 0.79 |
| Age | 1.00 | 0.76 | 1.01 | 0.42 | 0.99 | 0.29 |
| Tumor type (superficial) | 0.62 | 0.27 | 0.22 | 0.005** | 0.49 | 0.03* |
| Tumor type (infiltrative) | 1.39 | 0.52 | 1.57 | 0.33 | 0.86 | 0.72 |
| T-factor (T2 vs T1) | 1.63 | 0.27 | 1.05 | 0.92 | 1.14 | 0.69 |
| Prescribed dose | 0.99 | 0.90 | 0.93 | 0.32 | 0.96 | 0.46 |
AHR = adjusted hazard ratio. *P < 0.05, **P < 0.01.